Biogen (BIIB) Tops Q3 EPS by 22c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/14/2026
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Biogen Reports Record Third Quarter 2016 Revenues of $3.0 Billion
October 26, 2016 6:59 AM EDTThird quarter 2016 GAAP diluted EPS rise 13%; Non-GAAP diluted EPS rise 16%
Nusinersen filed with FDA and EMA for spinal muscular atrophy based on positive interim analysis of ENDEAR trial
Phase 3 Alzheimers disease candidate aducanumab receives FDA Fast Track designation
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Biogen Inc. (NASDAQ: BIIB) today reported third quarter 2016 financial results, including:
Total revenues of $3.0 billion, a 6% increase versus the same quarter in the prior year. Growth was driven by a 10% increase in worldwide TECFIDERA®... More